Developing the Keys to Unlock Cancer Cures
ImmunoKey is developing a first-in-class platform technology to unlock the potential of CAR T-cell therapy for solid cancers.
We are tackling ovarian cancer with our lead product; a disease that is marked by high relapse rates and poor patient outcomes. With over 7,500 new cases each year in the UK, and more than 200,000 deaths worldwide annually, there is a clear need for more effective therapies.
At ImmunoKey, we are addressing this challenge. Our integrated technologies are designed with the goal of bringing durable responses to patients with limited treatment options.
Our Vision
To establish innovative cell therapies that improve the survival and quality of life of patients with cancer
Our Mission
Our rigorous and collaborative research is driven by a commitment to improving patient survival and quality of life. Putting integrity and compassion at the heart of our work ethic, ImmunoKey’s mission is to push the boundaries of immunotherapy by developing safe, effective, and accessible cell therapies